Women’s Heart Health: Recognizing Cardiovascular Risk Early

Abstract

Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality in women worldwide, yet its presentation, risk profile, and outcomes are uniquely influenced by sex-specific factors. Early recognition of cardiovascular risk in women is complicated by atypical symptomatology, underdiagnosis, and gender disparities in research and clinical care. This review synthesizes current evidence on epidemiology, pathophysiology, risk factors, clinical features, diagnostic strategies, management, recent advances, and guideline recommendations, providing clinicians with a nuanced framework for optimizing prevention and care in women. Emphasis is placed on integrating mechanism-based insights and practical implications for improving early risk identification and patient outcomes.

Introduction

Despite advances in cardiovascular medicine, the global burden of CVD in women remains substantial. Historically considered a "male disease," CVD in women has received less attention, resulting in knowledge gaps and suboptimal outcomes. Unique hormonal influences, sex-specific risk factors, and atypical clinical features necessitate a tailored approach to risk assessment and management. This review aims to equip clinicians with evidence-based, guideline-driven strategies for recognizing and mitigating cardiovascular risk in women, supporting the delivery of equitable and effective care.

Epidemiology / Disease Burden

Globally, CVD accounts for approximately one in every three female deaths, surpassing mortality from all forms of cancer combined. The incidence of myocardial infarction (MI) in women increases sharply post-menopause, with women experiencing higher mortality rates following acute coronary events compared to men. Epidemiological studies highlight significant underdiagnosis and undertreatment in women, particularly among younger and minority populations. Stroke, heart failure, and peripheral arterial disease also exhibit sex-related differences in prevalence and prognosis, underscoring the need for heightened vigilance and early risk recognition in clinical practice.

Pathophysiology

The pathophysiology of CVD in women is shaped by both traditional atherosclerotic mechanisms and unique sex-specific factors. Endogenous estrogen exerts protective vascular effects through modulation of lipid profiles, endothelial function, and inflammatory pathways. However, menopause marks a decline in estrogen, accelerating atherogenesis and vascular stiffening. Women are more likely to develop microvascular dysfunction, plaque erosion (as opposed to rupture), and spontaneous coronary artery dissection. Conditions such as preeclampsia and polycystic ovary syndrome (PCOS) further modify cardiovascular risk through persistent metabolic and vascular disturbances.

Risk Factors

In addition to traditional risk factors (hypertension, diabetes, dyslipidemia, smoking, and family history), women face several unique and underappreciated risk modifiers. Adverse pregnancy outcomes including preeclampsia, gestational diabetes, and preterm delivery confer a long-term increase in CVD risk. Autoimmune diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis) are more prevalent in women and independently elevate cardiovascular risk. Psychosocial stressors, depression, and socioeconomic factors also disproportionately affect women, compounding risk. Recognition and documentation of these factors in the clinical setting are critical for accurate risk stratification.

Clinical Features

Women commonly present with atypical or less recognized symptoms during acute coronary syndromes, such as fatigue, dyspnea, nausea, and back or jaw pain, rather than classic chest pain. This can delay diagnosis and treatment, contributing to worse outcomes. Higher rates of heart failure with preserved ejection fraction (HFpEF), microvascular angina, and non-obstructive coronary artery disease are also noted in women, emphasizing the need for heightened clinical suspicion and tailored diagnostic algorithms.

Diagnosis

Diagnostic evaluation in women should incorporate a high index of suspicion for atypical presentations. Risk assessment tools such as the ASCVD Risk Estimator Plus may underestimate true risk in women, particularly those with sex-specific risk factors. Noninvasive imaging techniques including stress echocardiography, cardiac MRI, and coronary CT angiography offer value in evaluating ischemia and microvascular dysfunction. Biomarker interpretation, such as high-sensitivity troponin, may differ by sex and should be contextualized accordingly. Early and accurate diagnosis is paramount to improving outcomes.

Treatment & Management

Management of CVD in women encompasses both pharmacologic and lifestyle interventions, guided by evidence-based secondary prevention strategies. Statins, antihypertensives, antiplatelets, and glycemic control remain foundational, with attention to sex-specific responses and adverse event profiles. Aggressive risk factor modification, including smoking cessation and weight management, is essential. Cardiac rehabilitation programs tailored to women can improve participation and outcomes. Addressing psychosocial barriers and ensuring equitable access to care are critical components of comprehensive management.

Recent Advances / Emerging Therapies

Recent research has expanded understanding of sex-specific pathophysiology and therapeutic targets. The role of inflammation and immune dysregulation in female CVD is under active investigation, with novel agents targeting inflammatory pathways showing promise. SGLT2 inhibitors and GLP-1 receptor agonists have demonstrated cardiovascular benefit in women with diabetes. Ongoing trials are evaluating the safety and efficacy of hormone-based therapies for primary and secondary prevention. Advances in precision medicine, including genetic risk prediction and biomarker discovery, hold potential for individualized risk assessment and treatment.

Guideline Recommendations

Current guidelines from the American Heart Association (AHA), European Society of Cardiology (ESC), and other professional bodies emphasize the importance of sex-specific risk assessment and management. Recommendations include routine assessment of pregnancy history, autoimmune disease, and psychosocial risk factors in all women. Risk-enhancing factors should inform shared decision-making regarding statin initiation and other preventive measures. Guidelines advocate for increased awareness of atypical presentations and encourage research focused on sex differences in CVD.

Conclusion

Early recognition of cardiovascular risk in women demands a comprehensive, sex-specific approach that integrates epidemiological data, mechanistic insights, and clinical expertise. By understanding unique risk factors, atypical presentations, and emerging therapies, clinicians can more effectively identify at-risk women, initiate timely interventions, and improve long-term outcomes. Ongoing research and continued advocacy are essential to closing the gender gap in cardiovascular health and ensuring equitable, evidence-based care for all women.